FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3029332205> ?p ?o ?g. }

• W3029332205 abstract "e19387 Background: The combination of nivolumab and ipilimumab was found to improve overall survival compared to chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC) in the Checkmate 227 trial. However, nivolumab and ipilimumab are significantly more expensive than chemotherapy, and given the high incidence of advanced lung cancer, incorporating dual checkpoint inhibitors into the standard of care could have substantial economic consequences. In this study, we evaluated the cost effectiveness of combination ipilimumab and nivolumab for the treatment of advanced NSCLC. Methods: We designed a Markov model simulating the three treatment arms of the Checkmate 227 trial: nivolumab plus ipilimumab, nivolumab monotherapy, and chemotherapy. Transition probabilities, such as disease progression, survival, and treatment toxicities, were derived from trial data. Costs (in 2019 United States dollars) and health utilities were estimated from published literature. Incremental cost-effectiveness ratios (ICERs), expressed as dollar per quality-adjusted life-year (QALY), were calculated, with results less than $100,000/QALY considered cost-effective from a healthcare payer perspective. We assessed model uncertainty with one-way and probabilistic sensitivity analyses. Results: In our base-case model, nivolumab and ipilimumab combination therapy increased overall cost by $227,700 and improved effectiveness by 0.55 QALY compared to chemotherapy, resulting in an ICER of $413,400/QALY. Nivolumab monotherapy increased overall cost by $98,500 and improved effectiveness by 0.05 QALY compared to chemotherapy, resulting in an ICER of $1,885,400/QALY. Our model was most sensitive to both the cost and duration of dual immunotherapy. Combination immunotherapy became cost effective at an ICER under $100,000/QALY if monthly costs of treatment were reduced from $26,586 to $8,844 (a 67% reduction) or if maximum allowed duration of immunotherapy was reduced from 24 to 4 months. The model was not sensitive to assumptions about survival differences between the study arms. Probabilistic sensitivity analysis showed that at a willingness-to-pay threshold of $100,000/QALY, dual immunotherapy was less cost-effective than chemotherapy 99.99% of the time. Conclusions: Combination nivolumab and ipilimumab immunotherapy is not cost-effective at current prices despite increasing overall survival for patients with advanced NSCLC." @default.
• W3029332205 created "2020-06-05" @default.
• W3029332205 creator A5003790740 @default.
• W3029332205 creator A5043763331 @default.
• W3029332205 creator A5064099533 @default.
• W3029332205 creator A5070356766 @default.
• W3029332205 creator A5083199205 @default.
• W3029332205 creator A5084204364 @default.
• W3029332205 date "2020-05-20" @default.
• W3029332205 modified "2023-10-16" @default.
• W3029332205 title "Cost effectiveness of combination ipilimumab-nivolumab in advanced non-small-cell lung cancer." @default.
• W3029332205 doi "https://doi.org/10.1200/jco.2020.38.15_suppl.e19387" @default.
• W3029332205 hasPublicationYear "2020" @default.
• W3029332205 type Work @default.
• W3029332205 sameAs 3029332205 @default.
• W3029332205 citedByCount "2" @default.
• W3029332205 countsByYear W30293322052021 @default.
• W3029332205 crossrefType "journal-article" @default.
• W3029332205 hasAuthorship W3029332205A5003790740 @default.
• W3029332205 hasAuthorship W3029332205A5043763331 @default.
• W3029332205 hasAuthorship W3029332205A5064099533 @default.
• W3029332205 hasAuthorship W3029332205A5070356766 @default.
• W3029332205 hasAuthorship W3029332205A5083199205 @default.
• W3029332205 hasAuthorship W3029332205A5084204364 @default.
• W3029332205 hasConcept C112930515 @default.
• W3029332205 hasConcept C121608353 @default.
• W3029332205 hasConcept C126322002 @default.
• W3029332205 hasConcept C143998085 @default.
• W3029332205 hasConcept C2776256026 @default.
• W3029332205 hasConcept C2777701055 @default.
• W3029332205 hasConcept C2780030458 @default.
• W3029332205 hasConcept C2781433595 @default.
• W3029332205 hasConcept C3019080777 @default.
• W3029332205 hasConcept C71924100 @default.
• W3029332205 hasConceptScore W3029332205C112930515 @default.
• W3029332205 hasConceptScore W3029332205C121608353 @default.
• W3029332205 hasConceptScore W3029332205C126322002 @default.
• W3029332205 hasConceptScore W3029332205C143998085 @default.
• W3029332205 hasConceptScore W3029332205C2776256026 @default.
• W3029332205 hasConceptScore W3029332205C2777701055 @default.
• W3029332205 hasConceptScore W3029332205C2780030458 @default.
• W3029332205 hasConceptScore W3029332205C2781433595 @default.
• W3029332205 hasConceptScore W3029332205C3019080777 @default.
• W3029332205 hasConceptScore W3029332205C71924100 @default.
• W3029332205 hasFunder F4320332161 @default.
• W3029332205 hasLocation W30293322051 @default.
• W3029332205 hasOpenAccess W3029332205 @default.
• W3029332205 hasPrimaryLocation W30293322051 @default.
• W3029332205 hasRelatedWork W10297767 @default.
• W3029332205 hasRelatedWork W10602865 @default.
• W3029332205 hasRelatedWork W10640851 @default.
• W3029332205 hasRelatedWork W10741706 @default.
• W3029332205 hasRelatedWork W19759200 @default.
• W3029332205 hasRelatedWork W3586763 @default.
• W3029332205 hasRelatedWork W5217577 @default.
• W3029332205 hasRelatedWork W6195560 @default.
• W3029332205 hasRelatedWork W8388642 @default.
• W3029332205 hasRelatedWork W9894749 @default.
• W3029332205 isParatext "false" @default.
• W3029332205 isRetracted "false" @default.
• W3029332205 magId "3029332205" @default.
• W3029332205 workType "article" @default.